Moneycontrol

Budget 2021

Associate Partners:

  • SMC
  • Samsung
  • Volvo

Moneycontrol

Budget 2021

Associate Partners:

  • SMCSamsungVolvo
results
Jump to
59 Results Found
  • Cadila Healthcare Q3 PAT seen up 37.6% YoY to Rs. 373.9 cr: Prabhudas Lilladher Jan 18, 2021 10:52 PM IST

    Cadila Healthcare Q3 PAT seen up 37.6% YoY to Rs. 373.9 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 5.3 percent Y-o-Y (up 0.3 percent Q-o-Q) to Rs. 3,638.1 crore, according to Prabhudas Lilladher.

  • Cadila Healthcare Q2 PAT may dip 23% YoY to Rs. 321.5 cr: Emkay Oct 14, 2019 03:49 PM IST

    Cadila Healthcare Q2 PAT may dip 23% YoY to Rs. 321.5 cr: Emkay

    Net Sales are expected to increase by 17.4 percent Y-o-Y (down 0.6 percent Q-o-Q) to Rs. 3,475.2 crore, according to Emkay.

  • Cadila Healthcare Q1 PAT may dip 22.4% YoY to Rs. 366.7 cr: Prabhudas Lilladher Jul 12, 2019 04:33 PM IST

    Cadila Healthcare Q1 PAT may dip 22.4% YoY to Rs. 366.7 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 13.9 percent Y-o-Y (down 11.7 percent Q-o-Q) to Rs. 3,296.1 crore, according to Prabhudas Lilladher.

  • Cadila Healthcare Q4 PAT may dip 28.9% YoY to Rs. 419.9 cr: Prabhudas Lilladher Apr 12, 2019 12:52 PM IST

    Cadila Healthcare Q4 PAT may dip 28.9% YoY to Rs. 419.9 cr: Prabhudas Lilladher

    Net Sales are expected to decrease by 3.6 percent Y-o-Y (down 12.4 percent Q-o-Q) to Rs. 3,134.8 crore, according to Prabhudas Lilladher.

  • Cadila Q3 PAT may dip 29.7% YoY to Rs. 382 cr: Sharekhan Jan 18, 2019 01:53 PM IST

    Cadila Q3 PAT may dip 29.7% YoY to Rs. 382 cr: Sharekhan

    Net Sales are expected to decrease by 6.7 percent Y-o-Y (up 2.8 percent Q-o-Q) to Rs. 3,043 crore, according to Sharekhan.

  • Cadila Healthcare Q3 PAT may dip 12.8% YoY to Rs. 473.7 cr: ICICI Direct Jan 11, 2019 05:28 PM IST

    Cadila Healthcare Q3 PAT may dip 12.8% YoY to Rs. 473.7 cr: ICICI Direct

    Net Sales are expected to decrease by 1.1 percent Y-o-Y (up 8.8 percent Q-o-Q) to Rs. 3,222.2 crore, according to ICICI Direct.

  • Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila Jan 04, 2019 10:45 AM IST

    Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila

    For Lupin, Credit Suisse sees margin improving but weak Tamiflu season could be an overhang.

  • Cadila Healthcare Q2 PAT seen up 4.8% YoY to Rs. 530 cr: HDFC Securities Oct 17, 2018 05:55 PM IST

    Cadila Healthcare Q2 PAT seen up 4.8% YoY to Rs. 530 cr: HDFC Securities

    Net Sales are expected to decrease by 5.2 percent Y-o-Y (up 5.9 percent Q-o-Q) to Rs. 3,070 crore, according to HDFC Securities.

  • Cadila Q2 PAT may dip 23.3% YoY to Rs. 386 cr: Sharekhan Oct 16, 2018 06:57 PM IST

    Cadila Q2 PAT may dip 23.3% YoY to Rs. 386 cr: Sharekhan

    Net Sales are expected to decrease by 4.4 percent Y-o-Y (up 8.1 percent Q-o-Q) to Rs. 3,093 crore, according to Sharekhan.

  • Cadila Healthcare Q2 PAT may dip 25.4% YoY to Rs. 375.4 cr: ICICI Direct Oct 12, 2018 04:30 PM IST

    Cadila Healthcare Q2 PAT may dip 25.4% YoY to Rs. 375.4 cr: ICICI Direct

    Net Sales are expected to decrease by 7.6 percent Y-o-Y (up 3.2 percent Q-o-Q) to Rs. 2,986.6 crore, according to ICICI Direct.

  • Pharma Q1 preview: Poised for strong performance on rebound of domestic and stable US generics biz Jul 12, 2018 09:42 PM IST

    Pharma Q1 preview: Poised for strong performance on rebound of domestic and stable US generics biz

    "For the first time after six consecutive quarters, the pharma companies under our coverage will report double digit YoY growth of 13 percent in revenues,” said HDFC Securities

  • Global brokerages upgrade these 6 stocks to buy post Q4 results May 09, 2018 08:46 AM IST

    Global brokerages upgrade these 6 stocks to buy post Q4 results

    Global brokerage houses have upgraded a few stocks, highlighting robust Q4 FY18 results. Moneycontrol takes a look at six such stocks which have seen a ratings upgrade

  • Cadila Healthcare Q4 PAT seen up 36.5% YoY to Rs. 530 cr: HDFC Securities Apr 20, 2018 12:52 PM IST

    Cadila Healthcare Q4 PAT seen up 36.5% YoY to Rs. 530 cr: HDFC Securities

    Net Sales are expected to increase by 24 percent Y-o-Y (down 5.7 percent Q-o-Q) to Rs. 3,070 crore, according to HDFC Securities.

  • Cadila Healthcare Q4 PAT seen up 39.7% YoY to Rs. 538.4 cr: Edelweiss Apr 16, 2018 06:01 PM IST

    Cadila Healthcare Q4 PAT seen up 39.7% YoY to Rs. 538.4 cr: Edelweiss

    Net Sales are expected to increase by 27.7 percent Y-o-Y (down 2.9 percent Q-o-Q) to Rs. 3,163.5 crore, according to Edelweiss.

  • Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key Apr 12, 2018 05:53 PM IST

    Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key

    Analysts predict the last quarter of FY18 to be mixed bag with revenues expected to remain almost flat to a growth of lower single digit on year-on-year basis. The net profit is predicted to decline by around 9-10 percent.

  • Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key Jan 18, 2018 08:36 AM IST

    Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key

    As Indian drug makers brace up to report their third quarter earnings in the days ahead, analysts predict Q3 FY18 to be mixed bag with revenues expected to remain flat on year-on-year basis, though on sequential basis things may look much better.

  • Weak US sales, INR appreciation to drag earnings; Dr Reddy, Cadila top pick: Edelweiss Jan 11, 2018 04:06 PM IST

    Weak US sales, INR appreciation to drag earnings; Dr Reddy, Cadila top pick: Edelweiss

    The USFDA granted 246 nods in Q3FY18, which is the highest-ever approvals in a single quarter. Cadila Healthcare received 23 and Aurobindo Pharma got 18 approvals.

  • Cadila Q4 PAT seen up 19.5% to Rs 309.7 cr: ICICI Securities Apr 17, 2017 01:13 PM IST

    Cadila Q4 PAT seen up 19.5% to Rs 309.7 cr: ICICI Securities

    Net Sales are expected to increase by 5.8 percent Q-o-Q (down 0.4 percent Y-o-Y) to Rs 2434.2 crore, according to ICICI Securities. Cadila to report net profit at 309.7 crore up 19.5% quarter-on-quarter.

  • Cadila Q4 PAT seen up 19.5% to Rs 309.7 cr: ICICI Securities Apr 17, 2017 01:13 PM IST

    Cadila Q4 PAT seen up 19.5% to Rs 309.7 cr: ICICI Securities

    Net Sales are expected to increase by 5.8 percent Q-o-Q (down 0.4 percent Y-o-Y) to Rs 2434.2 crore, according to ICICI Securities. Cadila to report net profit at 309.7 crore up 19.5% quarter-on-quarter.

  • Cadila Q3 PAT seen up 8.7% to Rs 390.3 cr: ICICI Securities Jan 14, 2017 02:22 PM IST

    Cadila Q3 PAT seen up 8.7% to Rs 390.3 cr: ICICI Securities

    Net Sales are expected to increase by 7.1 percent Q-o-Q (up 4.9 percent Y-o-Y) to Rs 2535.1 crore, according to ICICI Securities.

  • Cadila Healthcare Q3 PAT seen up 9.5% to Rs 369.6 cr: KR Choksey Jan 13, 2017 12:29 PM IST

    Cadila Healthcare Q3 PAT seen up 9.5% to Rs 369.6 cr: KR Choksey

    Net Sales are expected to increase by 7.5 percent Q-o-Q (up 7.3 percent Y-o-Y) to Rs 2512.6 crore, according to KR Choksey.

  • Cadila Health Q2 profit seen up 2%, margin may shrink on biz mix Oct 26, 2016 10:42 AM IST

    Cadila Health Q2 profit seen up 2%, margin may shrink on biz mix

    Pharma company Cadila Healthcare is expected to report a 2.3 percent growth in second quarter profit at Rs 399.83 crore and 0.7 percent rise in revenue at Rs 2,477.2 crore on yearly basis, according to average of estimates of analysts polled by CNBC-TV18.

  • Cadila HC Q1 PAT seen down by 8.8% at Rs 354.6 cr: Religare Jul 16, 2016 01:15 PM IST

    Cadila HC Q1 PAT seen down by 8.8% at Rs 354.6 cr: Religare

    Sales are expected to increase by 0.2 percent Q-o-Q (down 1.9 percent Y-o-Y) to Rs 2453.8 crore, according to Religare Research.

  • Cadila Q1 PAT seen down 1.9% to Rs 381.2 cr: Edelweiss Jul 14, 2016 06:07 PM IST

    Cadila Q1 PAT seen down 1.9% to Rs 381.2 cr: Edelweiss

    Net Sales are expected to increase by 3.4 percent Q-o-Q (up 4.3 percent Y-o-Y) to Rs 2532.4 crore, according to Edelweiss

  • Cadila Health Q4 net may rise 7%, R&D likely to hurt margins May 13, 2016 09:30 AM IST

    Cadila Health Q4 net may rise 7%, R&D likely to hurt margins

    During the quarter, EBITDA may increase 11 percent to Rs 551 crore compared to Rs 496 crore while operating profit margin may stand at 22 percent from 21.7 percent year-on-year.

Sections